

Ronald Herbst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7996022/publications.pdf>

Version: 2024-02-01

29
papers

2,257
citations

304743

22
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

4997
citing authors

#	ARTICLE	IF	CITATIONS
1	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	8.2	423
2	<i>TP53</i> , <i>STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	7.0	257
3	Microglia-dependent synapse loss in type I interferon-mediated lupus. <i>Nature</i> , 2017, 546, 539-543.	27.8	173
4	Cell Distance Mapping Identifies Functional T Follicular Helper Cells in Inflamed Human Renal Tissue. <i>Science Translational Medicine</i> , 2014, 6, 230ra46.	12.4	162
5	Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. , 2019, 7, 244.		125
6	B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 213-222.	2.5	119
7	IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression. <i>Journal of Immunology</i> , 2017, 199, 3316-3325.	0.8	103
8	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	4.4	88
9	Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses. <i>Immunity</i> , 2017, 46, 106-119.	14.3	84
10	Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. <i>Journal of Clinical Medicine</i> , 2016, 5, 107.	2.4	76
11	A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	68
12	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 928-940.	5.6	62
13	SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. <i>Clinical Cancer Research</i> , 2018, 24, 6570-6582.	7.0	56
14	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 844-856.	1.1	55
15	Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. <i>Leukemia</i> , 2019, 33, 766-771.	7.2	49
16	The Plasma Cell Signature in Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 173-184.	5.6	47
17	Molecular-based diagnosis of multiple sclerosis and its progressive stage. <i>Annals of Neurology</i> , 2017, 82, 795-812.	5.3	45
18	CD19 and CD32b Differentially Regulate Human B Cell Responsiveness. <i>Journal of Immunology</i> , 2014, 192, 1480-1490.	0.8	44

#	ARTICLE	IF	CITATIONS
19	Preclinical Evaluation of MEDI0641, a Pyrrolbenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1576-1587.	4.1	37
20	Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. <i>Oncotarget</i> , 2017, 8, 65090-65099.	1.8	34
21	Characterisation of innate lymphoid cell populations at different sites in mice with defective T cell immunity. <i>Wellcome Open Research</i> , 2017, 2, 117.	1.8	27
22	A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 689-701.	4.1	25
23	Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice. <i>Journal of Immunology</i> , 2016, 197, 491-503.	0.8	23
24	Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolbenzodiazepine Dimers with and without PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 89-99.	4.1	19
25	ICOS is required for the generation of both central and effector CD4 + memory T cell populations following acute bacterial infection. <i>European Journal of Immunology</i> , 2015, 45, 1706-1715.	2.9	16
26	Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. <i>Oncotarget</i> , 2018, 9, 22960-22975.	1.8	13
27	CD47 limits antibody dependent phagocytosis against non-malignant B cells. <i>Molecular Immunology</i> , 2017, 85, 57-65.	2.2	9
28	Immunofibroblasts regulate LT α 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	4.4	8
29	Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring. <i>Reproductive Toxicology</i> , 2017, 74, 116-133.	2.9	7